Entries for the 2021 competition are well underway and PharmaTimes are calling on pharma marketers in a variety of roles to step forward and enter.
News
Merck KGaA and BioMed X launch new joint cancer research programme
New partnership will explore the role of extrachromosomal DNA in cancer
GSK and Alector ink neurodegenerative diseases partnership
Under the terms of the collaboration, Alector could receive up to $1.5bn in milestone payments
Over 600,000 COVID-19 tests genomically sequenced in the UK
The UK is estimated to contribute around 23% of all COVID-19 sequencing uploaded to GISAID
Queen awards the George Cross to the NHS for 73 years of service
The Queen has awarded the ‘unprecedented’ honour to staff for their response to the COVID-19 pandemic
Nonacus partners with Birmingham University to develop bladder cancer test
Nonacus is aiming to launch the ‘highly sensitive’ non-invasive bladder cancer test within 12 months
MHRA authorises Diurnal’s CAH therapy Efmody
Congenital adrenal hyperplasia (CAH) is a rare condition caused by deficiency of adrenal enzymes
Jazz Pharma’s blood cancer therapy Rylaze wins US approval
Rylaze has been specifically developed for patients who have developed hypersensitivity to E.coli-derived asparaginase
AZ says MPO inhibitor AZD4831 shows promise in heart failure study
AZD4831 is being investigated in patients with heart failure with preserved ejection fraction (HFpEF)
MSD’s Keytruda scores EU approval in certain oesophageal cancer patients
Checkpoint inhibitor approved in combination with chemotherapy in the first-line setting for these patients
Rinvoq scores positive results as a maintenance therapy for ulcerative colitis
JAK inhibitor hit primary endpoint of improved clinical remission at 52 weeks in maintenance study
Highest ever number of HCPs named on Disclosure UK, says ABPI
Data also shows pharma companies worked with fewer HCPS and HCOs in 2020 compared to 2019
JCVI recommends booster COVID-19 jabs for most vulnerable groups
Interim advice says boosters could be offered to priority groups from September
Gilead seeks US approval for long-acting HIV drug lenacapavir
Lenacapavir is designed to inhibit HIV-1 replication by interfering with a number of ‘essential’ steps in the viral lifecycle
MHRA approves Paion’s ‘ultra-short-acting’ anaesthetic Byfavo
The approval of Byfavo is based on data from a US-based Phase III clinical trial programme in procedural sedation
